1. Bush K, Fisher JF. Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from Gram-negative bacteria. Annu Rev Microbiol. 2011 (65):455-78. [
PubMed]
2. Zahar JR, Lortholary O, Martin C, Potel G, Plesiat P, Nordmann P. Addressing the challenge of extended-spectrum β-lactamases. Curr Opin Investig Drugs 2009 Feb (10):172-80. [
PubMed]
3. Carattoli A. Resistance plasmid families in Enterobacteriaceae. Antimicrob Agents Chemother. 2009 Jun (53):2227-38. [
Article]
4. Pitout JD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis 2008 Mar (8):159–66. [
PubMed]
5. Chaudhary U, Agarwal R. Extended spectrum-lactamases (ESBL) - an emerging threat to clinical therapeutics. Indian J Med Microbiol 2004 Apr-Jun (22): 75–80. [
PubMed]
6. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005 Oct (18): 657–86. [
PubMed]
7. Giske CG, Sundsfjord AS, Kahlmeter G, Woodford N, Nordmann P, Paterson DL, et al. Redefining extended-spectrum beta-lactamases: Balancing science and clinical need. J Antimicrob Chemother 2009 Jan (63):1–4. [
PubMed]
8. Bush K, Jacoby GA. Updated functional classification of β-lactamases. Antimicrob Agents Chemother 2010 Mar (54):969 –976. [
PubMed]
9. Chaudhary U, Aggarwal R. Extended Spectrum β-Lactamases-An Emerging threat to Clinical therapeutics. Indian J Med Microbiol. 2004 Apr-Jun (22):75–80. [
PubMed]
10. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended-spectrum β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2006 Apr (50):1257-62. [
PubMed]
11. Kluytmans-Vandenberg MF, Kluytmans JA, Voss A. Dutch guideline for preventing nosocomial transmission of highly resistantmicro-organisms (HRMO). Infection 2005 Oct (33):309–313. [
PubMed]
12. Eric S, Sanack B, Kocagoz T, Kocagoz S, Hascelik G. Rapid 4 to 6 hour detection of extended-spectrum beta-lactamases in a routine laboratory. Scand J Infect Dis 2007 (39): 781_785. [
PubMed]
13. Kocagoz T, Ercis S, Darka O, Salmanzadeh-Ahrabi S, Kocagoz S, Hasc¸elik G. Quicolor: a novel system for rapidantibacterial susceptibility testing. Ann Microbiol 2007 (57):131_135. [
Article]
14. Bolandghamatpoor Z, Abdi-Ali A, Salmanzadeh Ahrabi S. Design and Evaluation Rapid Antibacterial Susceptibility Testing for Enterobacteriaceae. Journal of Applied Biologiy of Alzahra University (Tehran, Iran) 2014 Winter (26):1-8.
15. Sajed R. Optimization of the colorimetric medium for antibacterial susceptibility test. M.Sc.Thesis. Alzahra University (Tehran, Iran) 2013.
16. Clinical and Laboratory Standards Institute (formerly NCCLS). Performance Standards for Antimicrobial susceptibilityTesting
17. Clinical and Laboratory Standards Institute (formerly NCCLS). Performance Standards for Antimicrobial susceptibilityTesting. 15th Informational Supplement M100-S23 CLSI, Wayne, PA, USA 2013. [
Article]
18. Ho PL, Ho AY, Chow KH, Wong RC, Duan RS, Ho WL and et al. Occurrence and molecular analysis of extendedspectrumbeta-lactamase-producing Proteus mirabilis inHong Kong, 1999_2002. J Antimicrob Chemother 2005 (55):/840_45. [
Article]
19. Linscott AJ, Brown WJ. Evaluation of 4 commercially available extended-spectrum beta-lactamase phenotypic confirmation tests. J Clin Microbiol 2005 (43):1081_1085. [
Article]